insights_auto
Why is DMYD-B up 5.52%?
Dive Deeperchevron_right
DMYD-B:STO
Diamyd Medical AB
SEK 1.07
arrow_upward
+5.52%(+0.056) 1D
Oct 13, 10:10:43 AM GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
SEK 1.03
High
SEK 1.08
Low
SEK 1.01
Mkt. cap
162.09M
Avg. vol.
796.34K
Volume
241.84K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.76
Shares outstanding
134.00M
No. of employees
42
Open
SEK 1.03
High
SEK 1.08
Low
SEK 1.01
Mkt. cap
162.09M
Avg. vol.
796.34K
Volume
241.84K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.76
Shares outstanding
134.00M
No. of employees
42
News stories
From web sources and news partners
FXLeaders
·
38 minutes ago
Dow Futures Hold Near 52.2K as Nasdaq Struggles Against Rising Bond Yields
Invezz
·
8 minutes ago
Jim Cramer says investors keep making this costly mistake as S&P 500 surges 118%
The Motley Fool
·
1 hour ago
If You Invest $5,000 in VOO Today, Here's What History Says It Could Be Worth in 20 Years
TradingView
·
2 hours ago
Stock Market: Will S&P 500 Open Up or Down Today?
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB